DE502004001289D1 - PYRROLIDIN-1,2-DICARBONSÄURE-1-i(4-ETHINYL-PHENYL)-AMIDö-2-i(PHENYL)-AMIDö DERIVATE ALS INHIBITOREN DER KOAGULATIONSFAKTOREN XA UND VIIA ZUR BEHANDLUNG VON THROMBOSEN - Google Patents

PYRROLIDIN-1,2-DICARBONSÄURE-1-i(4-ETHINYL-PHENYL)-AMIDö-2-i(PHENYL)-AMIDö DERIVATE ALS INHIBITOREN DER KOAGULATIONSFAKTOREN XA UND VIIA ZUR BEHANDLUNG VON THROMBOSEN

Info

Publication number
DE502004001289D1
DE502004001289D1 DE502004001289T DE502004001289T DE502004001289D1 DE 502004001289 D1 DE502004001289 D1 DE 502004001289D1 DE 502004001289 T DE502004001289 T DE 502004001289T DE 502004001289 T DE502004001289 T DE 502004001289T DE 502004001289 D1 DE502004001289 D1 DE 502004001289D1
Authority
DE
Germany
Prior art keywords
phenyl
amido
thromboses
ethinyl
viia
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE502004001289T
Other languages
German (de)
English (en)
Inventor
Werner Mederski
Christos Tsaklakidis
Dieter Dorsch
Bertram Cezanne
Johannes Gleitz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Patent GmbH
Original Assignee
Merck Patent GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE10327428A external-priority patent/DE10327428A1/de
Priority claimed from DE10329457A external-priority patent/DE10329457A1/de
Application filed by Merck Patent GmbH filed Critical Merck Patent GmbH
Publication of DE502004001289D1 publication Critical patent/DE502004001289D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Vascular Medicine (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DE502004001289T 2003-06-18 2004-05-27 PYRROLIDIN-1,2-DICARBONSÄURE-1-i(4-ETHINYL-PHENYL)-AMIDö-2-i(PHENYL)-AMIDö DERIVATE ALS INHIBITOREN DER KOAGULATIONSFAKTOREN XA UND VIIA ZUR BEHANDLUNG VON THROMBOSEN Expired - Lifetime DE502004001289D1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE10327428A DE10327428A1 (de) 2003-06-18 2003-06-18 Ethinylprolinderivate
DE10329457A DE10329457A1 (de) 2003-04-03 2003-07-01 Ethinylprolinderivate
PCT/EP2004/005717 WO2004110433A1 (de) 2003-06-18 2004-05-27 Pyrrolidin-1, 2- dicarbonsäure- 1- [(4- ethinyl- phenyl) - amid]- 2- [(phenyl)- amid] derivative als inhibitoren der koagulationsfaktoren xa und viia zur behandlung von thrombosen

Publications (1)

Publication Number Publication Date
DE502004001289D1 true DE502004001289D1 (de) 2006-10-05

Family

ID=33553467

Family Applications (1)

Application Number Title Priority Date Filing Date
DE502004001289T Expired - Lifetime DE502004001289D1 (de) 2003-06-18 2004-05-27 PYRROLIDIN-1,2-DICARBONSÄURE-1-i(4-ETHINYL-PHENYL)-AMIDö-2-i(PHENYL)-AMIDö DERIVATE ALS INHIBITOREN DER KOAGULATIONSFAKTOREN XA UND VIIA ZUR BEHANDLUNG VON THROMBOSEN

Country Status (16)

Country Link
US (1) US7557222B2 (https=)
EP (1) EP1633346B1 (https=)
JP (1) JP5015593B2 (https=)
KR (1) KR20060023154A (https=)
CN (1) CN1809346A (https=)
AR (1) AR044818A1 (https=)
AT (1) ATE337000T1 (https=)
AU (1) AU2004246766B2 (https=)
BR (1) BRPI0411466A (https=)
CA (1) CA2529453C (https=)
DE (1) DE502004001289D1 (https=)
ES (1) ES2271894T3 (https=)
MX (1) MXPA05013536A (https=)
PE (1) PE20050229A1 (https=)
TW (1) TW200504012A (https=)
WO (1) WO2004110433A1 (https=)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102004004731A1 (de) * 2004-01-30 2005-08-18 Merck Patent Gmbh Harnstoffderivate
DE102004016605A1 (de) * 2004-04-03 2005-10-20 Merck Patent Gmbh Thiocarbamoylproline
EP1951717A1 (en) 2005-11-16 2008-08-06 F.Hoffmann-La Roche Ag Novel pyrrolidine derivatives as inhibitors of coagulation factor xa
EP1818330A1 (de) 2006-02-14 2007-08-15 Boehringer Ingelheim Pharma GmbH & Co.KG Substituierte Prolinamide, deren Herstellung und deren Verwendung als Arzneimittel
MY146623A (en) * 2006-05-16 2012-09-14 Boehringer Ingelheim Int Substituted prolinamides, manufacturing, and the use thereof as medicaments
WO2009000878A1 (en) * 2007-06-28 2008-12-31 Novartis Ag Kallikrein 7 modulators
US8673920B2 (en) 2009-05-06 2014-03-18 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
WO2012058116A1 (en) 2010-10-27 2012-05-03 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
EP2632464B1 (en) 2010-10-29 2015-04-29 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
AU2012299227A1 (en) 2011-08-19 2014-02-20 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
WO2013039802A1 (en) 2011-09-16 2013-03-21 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
US8999990B2 (en) 2011-10-25 2015-04-07 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
EP2771004B1 (en) 2011-10-25 2016-05-18 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
EP2773206B1 (en) 2011-10-31 2018-02-21 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
EP2773351B1 (en) 2011-10-31 2017-08-23 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
WO2013066714A1 (en) 2011-10-31 2013-05-10 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
EP2790511B1 (en) 2011-12-16 2016-09-14 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
GB201209138D0 (en) * 2012-05-24 2012-07-04 Ono Pharmaceutical Co Compounds
AR092031A1 (es) 2012-07-26 2015-03-18 Merck Sharp & Dohme Inhibidores del canal de potasio medular externo renal
EP2925322B1 (en) 2012-11-29 2018-10-24 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
US9573961B2 (en) 2012-12-19 2017-02-21 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
WO2014126944A2 (en) 2013-02-18 2014-08-21 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
EP2968288B1 (en) 2013-03-15 2018-07-04 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
EP3027625B1 (en) 2013-07-31 2018-05-30 Merck Sharp & Dohme Corp. Spiro-fused derivatives of piperidine useful for the treatment of inter alia hypertension and acute or chronic heart failure
WO2015065866A1 (en) 2013-10-31 2015-05-07 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
JP6337750B2 (ja) * 2013-11-22 2018-06-06 小野薬品工業株式会社 化合物
KR20160107322A (ko) * 2014-01-14 2016-09-13 다이닛본 스미토모 세이야꾸 가부시끼가이샤 축합 ５－옥사졸리디논 유도체
WO2016127358A1 (en) 2015-02-12 2016-08-18 Merck Sharp & Dohme Corp. Inhibitors of renal outer medullary potassium channel
CN109796439B (zh) * 2019-01-18 2020-05-19 西安交通大学 一种羟脯氨酸类肽衍生物及其制备方法和应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU776053B2 (en) * 2000-03-31 2004-08-26 Astellas Pharma Inc. Diazepan derivatives or salts thereof
ATE368643T1 (de) 2001-03-30 2007-08-15 Millennium Pharm Inc Faktor xa benzamidin inhibitoren
US7312235B2 (en) * 2001-03-30 2007-12-25 Millennium Pharmaceuticals, Inc. Benzamide inhibitors of factor Xa
US7030141B2 (en) * 2001-11-29 2006-04-18 Christopher Franklin Bigge Inhibitors of factor Xa and other serine proteases involved in the coagulation cascade
DE102004014945A1 (de) * 2004-03-26 2005-10-13 Merck Patent Gmbh Prolinylderivate

Also Published As

Publication number Publication date
US20070093472A1 (en) 2007-04-26
CN1809346A (zh) 2006-07-26
KR20060023154A (ko) 2006-03-13
JP2006527708A (ja) 2006-12-07
AR044818A1 (es) 2005-10-05
TW200504012A (en) 2005-02-01
JP5015593B2 (ja) 2012-08-29
CA2529453C (en) 2012-10-02
WO2004110433A1 (de) 2004-12-23
MXPA05013536A (es) 2006-03-09
AU2004246766A1 (en) 2004-12-23
ES2271894T3 (es) 2007-04-16
EP1633346B1 (de) 2006-08-23
US7557222B2 (en) 2009-07-07
PE20050229A1 (es) 2005-04-12
AU2004246766B2 (en) 2009-09-17
ATE337000T1 (de) 2006-09-15
EP1633346A1 (de) 2006-03-15
CA2529453A1 (en) 2004-12-23
BRPI0411466A (pt) 2006-07-11

Similar Documents

Publication Publication Date Title
DE502004001289D1 (de) PYRROLIDIN-1,2-DICARBONSÄURE-1-i(4-ETHINYL-PHENYL)-AMIDö-2-i(PHENYL)-AMIDö DERIVATE ALS INHIBITOREN DER KOAGULATIONSFAKTOREN XA UND VIIA ZUR BEHANDLUNG VON THROMBOSEN
DE502004003688D1 (de) Pyrazolidin-1,2-dicarbonsäure-1-((phenyl)-amid)-2-((phenyl)-amid) derivate als koagulationsfaktor xa inhibitoren zur behandlung von thrombosen
DE502004009440D1 (de) Pyrrolidin-1,2-dicarbonsäure-1-(phenylamid)-2-(4-(3-oxo-morpholin-4-yl)-phenylamid) derivate und verwandte verbindungen als inhibitoren des koagulationsfaktors xa zur behandlung von thromboembolischen erkrankungen
DE602005026984D1 (de) Chinolin-derivate zur behandlung von latenter tuberkulose
DE60303238D1 (de) Pyrimidin-Essigsäure Derivate geeignet zur Behandlung von CRTH2-bedingten Krankheiten
DE602004020793D1 (de) 5-phenyl-4-methyl-thiazol-2-yl-amin-derivate als inhibitoren von phosphatidylinositol-3-kinase-enzymen (pi3) zur behandlung entzündlicher erkrankungen der luftwege
CY1118171T1 (el) Θεραπευτικη αντιμετωπιση της φαiνυλκετονουρiας me βη4
DE502006002886D1 (de) Dipyridyl-dihydropyrazolone und ihre verwendung 4- (pyridin-3-yl) -2- (pyridin-2-yl) -1,2-dihydro-3h-pyrazol-3-on derivate als spezifische hemmstoffe der hif-prolyl-4-hydroxylasen zur behandlung kardiovaskulärer und hämatologischer erkrankungen
DE502004004294D1 (de) Verfahren zur herstellung von pyrrolidin-1,2-dicarbonsäure-1 -(phenyl(-amid))-2-(phenyl(-amid)) derivaten und 1-(phenylcarbamoyl)-pyrrolidin-2-carbonsäurederivate als zwischenprodukte
EA200870019A1 (ru) Лактамовые соединения и способы их применения
CY1116754T1 (el) Παραγωγα νιτροκατεχολης ως αναστολεις της comt
ATE376835T1 (de) Verwendung von fucanen in der behandlung von adhäsion, arthritis und psoriasis
DE602004026891D1 (de) Tlr7-liganden zur behandlung von hepatitis c
ATE410430T1 (de) 2,3-dihydro-6-nitroimidazoä2,1- büoxazolverbindungen zur behandlung von tuberkulose
DE602005001929D1 (de) Sulfonamidderivate zur behandlung von krankheiten
DE502004005033D1 (de) Substituierte 2-aminotetraline zur behandlung von depressionen
DE602005017503D1 (de) Biphenyloxyessigsäure - derivate zur behandlung von atemwegserkränkungen
ATE375977T1 (de) Sulfonamidderivate zur behandlung von krankheiten
ATE505473T1 (de) Cyclopropylkondensierte indolobenzazepinderivate zur behandlung von hepatitis c
DE602005012481D1 (de) 2,7-substituierte 5-amino-4-hydroxy-8-(1h-indol-5-yl)-octanamid derivate als renin inhibitoren zur behandlung von bluthochdruck
ATE324889T1 (de) N-((3-oxo-2,3-dihydro-1h-isoindol-1- yl)acetyl)guanidin derivate als nhe1-inhibitoren zur behandlung von infarkten und angina pectoris
DE602004001134D1 (de) Tetrazolderivate und verfahren zur behandlung von stoffwechselbedingten erkrankungen damit
DE602004022035D1 (de) Verwendung von pthalide derivativen zur behandlung
ATE439347T1 (de) 7-(2h-pyrazol-3-yl)-3,5-dihydroxy-heptansäure- derivate als hmg-co-a-reductase-inhibitoren zur behandlung von lipidemia
DE502005007105D1 (de) 4-amino-5-oxo-8-phenyl-5h-pyrido-ä2,3-dü-pyrimidin-derivate als inhibitoren der tyrosinkinasen und der raf-kinasen zur behandlung von tumoren

Legal Events

Date Code Title Description
8364 No opposition during term of opposition